Basal-subtype Bladder Tumours Show a 'hot' Immunophenotype
Overview
Pathology
Affiliations
Aims: Basal and luminal molecular subgroups of muscle-invasive urothelial carcinoma (UC) can be recognised by the use of immunohistochemical markers. Studies have shown that responses to chemotherapy and outcomes differ among these subtypes. High-grade UC of the bladder is an immunogenic neoplasm that induces a substantial intratumoral and peritumoral immune response; the phenotype of infiltrating immune cells may yield prognostic information and predict response to therapy. In this study, we aimed to correlate the immunohistochemical phenotype of high-grade UC with immune microenvironment composition.
Methods And Results: Two hundred and thirty-five cases of high-grade UC treated with cystectomy were reviewed. Clinicopathological variables for each case were recorded, and disease-free survival at last follow-up was calculated. Invasive front inflammation and tumour-infiltrating lymphocytes were scored for each case. Two hundred and seven cases were used to construct a triplicate-core tissue microarray (TMA), with sections stained for cytokeratin (CK) 5/6 and GATA3. Of the evaluable cases, 167 were designated as luminal (CK5/6- and GATA3+) and 29 as basal (CK5/6+ and GATA3-). Additional sequential TMA sections were stained for CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) (SP263). Basal-subtype tumours showed a trend towards worse disease-specific survival (P = 0.078). There were statistically significant associations between basal subtype and CD8 expression (P = 0.008), PD-1 expression (P = 0.001), and PD-L1 expression (P = 0.014). Lower CD4/CD8 and increased CD8/FOXP3 ratios (P = 0.047 and P = 0.031, respectively) were also identified in the basal-subtype group.
Conclusions: Basal-subtype high-grade UC has an abundance of CD8+ T cells with increased expression of inhibitory markers, indicative of a 'hot' immunophenotype.
Cano Barbadilla T, Alvarez Perez M, Prieto Cuadra J, Dawid de Vera M, Alberca-Del Arco F, Garcia Munoz I Diagnostics (Basel). 2024; 14(22).
PMID: 39594166 PMC: 11592502. DOI: 10.3390/diagnostics14222501.
Sommer B, Dhawan D, Ruple A, Ramos-Vara J, Hahn N, Utturkar S Bladder Cancer. 2024; 7(3):317-333.
PMID: 38993617 PMC: 11181872. DOI: 10.3233/BLC-201523.
Conci N, Tassinari E, Tateo V, Rosellini M, Marchetti A, Ricci C Mol Diagn Ther. 2023; 28(1):37-51.
PMID: 37874465 DOI: 10.1007/s40291-023-00679-6.
Liu J, He Y, Zhou W, Tang Z, Xiao Z Front Pharmacol. 2023; 14:1280428.
PMID: 37818187 PMC: 10560734. DOI: 10.3389/fphar.2023.1280428.
Terlevic R, Ulamec M, Stimac G, Murgic J, Kruslin B Biomol Biomed. 2023; 23(6):968-975.
PMID: 37389960 PMC: 10655881. DOI: 10.17305/bb.2023.9242.